Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.
As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Publication Alerts
Subscribe to receive alerts once a paper has been published by Oncotarget.
On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control.
This malicious action will be reported to the FBI.
On August 25, 2022, the Office of Science and Technology Policy announced a new government policy legislating the immediate public release of all United States-funded research publications by 2025. Learn more here and here.
On May 23, 2023, the Council of the European Union adopted conclusions on high-quality, transparent, open, trustworthy, and equitable scholarly publishing. The Council calls for immediate and unrestricted open access to publishing research involving public funds. Learn more.
Targeting CD47/SIRPα "Do Not Eat Me" Axis: Advances and Challenges in Cancer Therapy
FOR IMMEDIATE RELEASE 2024-09-11
“Numerous phagocytosis checkpoints and ‘do not eat me’ signals (i.e., CD47, CD24, MHC-I, PD-L1, STC1, and GD2) have recently been recognized as potential therapeutic targets.”
As discussed in this paper, the growing understanding of the tumor immune microenvironment (TME) and its impact on treatment outcomes has led to advances in cancer therapy aimed at enhancing antitumor immune responses. While most current immunotherapies focus on T cells and immune checkpoint inhibitors (ICIs), there is increasing interest in targeting innate immune components, such as macrophages. Tumor-associated macrophages (TAMs) support tumor growth, metastasis, and angiogenesis, making them key targets for novel immunotherapies aimed at shifting the M2-like (pro-tumoral) macrophages to the M1-like (antitumoral) phenotype.
In their editorial, researchers Maria Gracia-Hernandez, Manasa Suresh, and Alejandro Villagra from Georgetown University Medical Center, highlight key phagocytosis checkpoints and “do not eat me” signals—such as CD47, CD24, MHC-I, PD-L1, STC1, and GD2—that have emerged as potential therapeutic targets.
The authors note that many tumor types overexpress CD47 to evade phagocytosis by interacting with SIRPα on macrophages. The editorial also summarizes challenges in targeting CD47 and potential solutions to overcome these obstacles.
“Overall, our understanding of this significant ‘do not eat me’ pathway over the years has resulted in the development of novel therapies and strategies to boost innate antitumor activity.”
Click hereto sign up for freeAltmetric alerts about this article.
About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Oncotarget is indexed and archived byPubMed/Medline,PubMed Central,Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:
